Narasimhan's Culture Club On Song At Novartis
Taking over at the Swiss firm as CEO in 2018, Vas Narasimhan set about creating an "inspired, curious and unbossed organization." Two years on, he has put the spotlight on several initiatives that are up and running on a number of fronts to achieve that goal.
You may also be interested in...
Dr Vas Narasimhan, a self-proclaimed history geek, is the current head of global development for Novartis Pharmaceuticals but he still considers himself a physician first when it comes to decision making.
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.